An announcement from Nearby Protein indicates that the company's stock closing price accumulated a deviation of over 30% across three consecutive trading days from October 28 to 30, constituting abnormal fluctuations in stock trading. The company stated that its AI-enabled high-throughput wet lab and data package services are still in the early stage of market expansion. As of the third quarter of 2026, revenue from the related business accounted for less than 2% of the company's total revenue. Given that the application of AI in drug R&D remains in its infancy, the company faces risks such as rapid technological iteration, long industry validation cycles, and significant challenges in commercial implementation. Future revenue and profit realization from the related business are subject to substantial uncertainty. Investors are advised to take a rational view and remain mindful of investment risks.